Impact Biomedical (NYSEAMERICAN:IBO) Releases Earnings Results

Impact Biomedical (NYSEAMERICAN:IBO) released its quarterly earnings data on Tuesday. The company reported ($0.02) EPS for the quarter, FiscalAI reports. The firm had revenue of $0.01 million during the quarter.

Impact Biomedical Price Performance

Impact Biomedical stock opened at $0.63 on Wednesday. The stock’s 50-day moving average is $0.61 and its 200-day moving average is $0.56. The company has a market cap of $67.39 million, a price-to-earnings ratio of -0.16 and a beta of 3.15. Impact Biomedical has a 12 month low of $0.36 and a 12 month high of $1.95.

Insider Activity at Impact Biomedical

In other news, Director Jason Grady sold 50,000 shares of the firm’s stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $0.65, for a total value of $32,500.00. Following the transaction, the director directly owned 250,182 shares in the company, valued at $162,618.30. This trade represents a 16.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 89.00% of the stock is currently owned by company insiders.

Impact Biomedical Company Profile

Impact Biomedical, Inc (“IBIO”) currently is a holding company operating mainly through our majority owned subsidiary, Global BioLife, Inc, which was incorporated on April 14, 2017. The Company is committed to both funding research and developing intellectual property portfolio. We currently focus on research in three main areas: (i) development of a universal therapeutic drug platform; (ii) a new sugar substitute; and (iii) a multi-use fragrance. IBIO discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships.